McKesson (NYSE:MCK) Stock Price Target Raised at Leerink Partners

McKesson (NYSE:MCK) had its price objective lifted by analysts at Leerink Partners from $1,030.00 to $1,070.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target points to a potential upside of 16.99% from the company’s previous close.

A number of other equities analysts have also commented on MCK. Citigroup lifted their price objective on McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Robert W. Baird set a $1,015.00 price target on shares of McKesson in a report on Thursday, August 6th. Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. Finally, Evercore reaffirmed an “outperform” rating on shares of McKesson in a research note on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $973.19.

McKesson Stock Performance

Shares of NYSE:MCK traded down $7.09 during mid-day trading on Wednesday, reaching $914.58. 277,542 shares of the company’s stock were exchanged, compared to its average volume of 937,255. McKesson has a twelve month low of $723.68 and a twelve month high of $999.00. The firm has a market capitalization of $106.63 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.82 and a beta of 0.30. The business’s fifty day moving average price is $881.95 and its 200-day moving average price is $832.66.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business had revenue of $105.38 billion during the quarter, compared to the consensus estimate of $103.88 billion. During the same period in the prior year, the business posted $8.26 earnings per share. McKesson’s quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Analysts predict that McKesson will post 44.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other McKesson news, Director Bradley Lerman sold 301 shares of McKesson stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO B Jr sold 111 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer directly owned 521 shares in the company, valued at $464,445.45. This trade represents a 17.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On McKesson

Several hedge funds and other institutional investors have recently modified their holdings of MCK. Moody National Bank Trust Division lifted its holdings in shares of McKesson by 4.9% in the 3rd quarter. Moody National Bank Trust Division now owns 1,433 shares of the company’s stock worth $1,224,000 after purchasing an additional 67 shares in the last quarter. Rosenberg Matthew Hamilton grew its position in McKesson by 2.8% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock valued at $347,000 after purchasing an additional 11 shares during the period. Baker Tilly Wealth Management LLC increased its stake in McKesson by 11.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 394 shares of the company’s stock valued at $337,000 after purchasing an additional 40 shares in the last quarter. Ferguson Wellman Capital Management Inc. increased its stake in McKesson by 1.6% during the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 28,674 shares of the company’s stock valued at $24,482,000 after purchasing an additional 438 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in McKesson by 5.1% during the third quarter. Versant Capital Management Inc now owns 558 shares of the company’s stock worth $476,000 after buying an additional 27 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson and CD&R agreed to acquire Option Care Health (NASDAQ: OPCH) for approximately $5.8 billion. The $32.05-per-share cash offer represents a 37% premium and expands McKesson’s exposure to home and alternate-site infusion services. CD&R will own approximately 51%, while McKesson will hold about 49%. CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
• Positive Sentiment: McKesson plans to invest approximately $1.4 billion in the transaction. The deal could provide long-term growth and diversification beyond traditional drug distribution, although it remains subject to shareholder and regulatory approvals. McKesson agrees to invest $1.4 billion in Option Care Health
• Positive Sentiment: Leerink Partners raised its price target for McKesson to $1,070 from $1,030, reinforcing the bullish analyst view and implying additional upside from recent trading levels. Leerink Partners Adjusts Price Target on McKesson
• Positive Sentiment: Reports indicated McKesson’s agreement with CVS was extended through 2032, improving visibility into a significant customer relationship and supporting the stock’s recent strength. McKesson stock gains as CVS pact extends to 2032
• Neutral Sentiment: McKesson is among the most-watched stocks on Zacks, but the report primarily discusses whether the shares remain attractive rather than announcing a new fundamental catalyst. Is Most-Watched Stock McKesson Worth Betting on Now?
• Negative Sentiment: Some commentary highlights McKesson’s thin net margin and negative book value, while the Option Care transaction introduces execution, financing and regulatory risks. These concerns could limit upside despite the favorable strategic rationale. McKesson margin and balance-sheet analysis

About McKesson

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.